Lead Product(s) : ORY-4001
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
ORYZON Announces Clinical Candidate Nomination of ORY-4001 for the Treatment of CNS Disorders
Details : ORY-4001 is a selective histone deacetylase 6 (HDAC-6) inhibitor, as clinical development candidate for the treatment of certain neurological diseases as Charcot-Marie-Tooth (CMT), Amyotrophic Lateral Sclerosis (ALS).
Product Name : ORY-4001
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 13, 2023
Lead Product(s) : ORY-4001
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : CMT Research Foundation
Deal Size : Undisclosed
Deal Type : Collaboration
ORYZON Collaborates with the CMT Research Foundation in the US
Details : Under this collaboration, CMTRF will be financing a series of in vivo tests with Oryzon’s HDAC6 candidates in a murine model of CMT1A, which reliably recapitulates many of the symptoms of this condition in humans.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
July 26, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : CMT Research Foundation
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : University of Minnesota
Deal Size : Undisclosed
Deal Type : Licensing Agreement
SOM Biotech Signs Licensing Agreement With the University of Minnesota
Details : This agreement follows the completion of research agreement, in which the University of Minnesota conducted a series of in vitro studies on potential pre-clinical product candidates for Duchenne and Becker muscular dystrophy identified using SOM Biotechâ...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
May 17, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : University of Minnesota
Deal Size : Undisclosed
Deal Type : Licensing Agreement